Dr. Parth Rali Provides Perspective to Healio on Results Presented at ERS on Mosliciguat

Parth M. Rali, MD, FCCP, Director of the Temple University Health System Pulmonary Embolism Response Team (PERT) Program and Section Temple Lung Pulmonary Vascular Disease Program, provided perspective for a Healio article on results presented at the European Respiratory Society (ERS) Congress on mosliciguat. Mosliciguat, a potential first-in-class inhaled medication, demonstrated significantly reduced pulmonary vascular resistance in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD) in the phase 2 PHocus study.